Pfizer (NYSE:PFE) Shares Down 0.5% - Should You Sell?

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) traded down 0.5% on Thursday . The company traded as low as $26.03 and last traded at $26.08. 5,951,264 shares changed hands during trading, a decline of 83% from the average session volume of 35,729,042 shares. The stock had previously closed at $26.21.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Bank of America reaffirmed a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Stock Up 0.1 %

The business's 50 day simple moving average is $26.17 and its 200 day simple moving average is $27.04. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $148.61 billion, a PE ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the business posted $0.10 earnings per share. The firm's revenue was up 24.7% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently modified their holdings of the business. Nordea Investment Management AB increased its stake in Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after purchasing an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI increased its stake in Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after buying an additional 159,984 shares during the period. NFJ Investment Group LLC lifted its holdings in Pfizer by 12.8% during the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock valued at $11,129,000 after buying an additional 43,719 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in Pfizer by 25.9% in the 3rd quarter. Daiwa Securities Group Inc. now owns 804,522 shares of the biopharmaceutical company's stock valued at $23,283,000 after buying an additional 165,611 shares during the period. Finally, Copley Financial Group Inc. bought a new position in Pfizer in the 3rd quarter worth about $577,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.